Takeda Files New Drug Application for Anticancer Drug
Takeda Pharmaceutical and Takeda Bio Development Center have submitted a new drug application of anti-cancer agent, panitumumab for the treatment of patients with progressed or relapse colorectal cancer to the Ministry of Health Labour and Welfare in Japan.
Panitumumab is a fully-human monoclonal antibody which binds to epidermal growth factor receptor and suppresses tumor growth. It shows a low incidence of allergic reaction upon and also after administration as it is a fully-human monoclonal antibody.
Masaomi Miyamoto, general manager of pharmaceutical development division of Takeda, said: “We expect to offer panitumumab as early as possible to the patients with colorectal cancer, which is increasing in number in Japan, and healthcare providers, as a new treatment option different from existing chemotherapies.”